Chongqing bids $93M for Bilthoven

China's Chongqing Zhifei Biological Products has bid $93 million (€65 million) in an auction of Dutch vaccine maker Bilthoven Biologicals, a spin-off of the Netherlands Vaccine Institute. Report

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.